Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-11-15
2005-11-15
Allen, Marianne P. (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000
Reexamination Certificate
active
06964947
ABSTRACT:
Formulations are provided comprising NGF and acetate-containing buffer from pH 5 to 6 that provide enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function.
REFERENCES:
patent: 5082774 (1992-01-01), Heinrich
patent: 5210185 (1993-05-01), Della Valle et al.
patent: 5457034 (1995-10-01), Della Valle et al.
patent: 5763394 (1998-06-01), O'Connor et al.
patent: 6277828 (2001-08-01), Knepp et al.
patent: WO 94/26302 (1994-11-01), None
patent: WO 95/05845 (1995-03-01), None
Apfel et al. (1991) Nerve growth factor prevents toxic neuropathy in mice. Ann.Neurol. 29(1):87-90.
Apfel et al. (1992) Never growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 31:76-80.
Bothwell et al. (1977) Dissociation equilibrium constant of β nerve growth factor. The Journal of Biological Chemistry. 252(23):8532-8536.
Canova-Davis et al. Amino-thermal serine to glycine post-translational modification observed in nerve growth factor biosynthesized in Chinese hamster ovary cells. Analytical Methods. pp. 230-231.
Calbiochem (1994/1995) Product Catalog. p. 233.
De Young et al. (1994) Temperature and PH dependence of recombinant human nerve growth factor dimer dissociation. Biophys.Journal 66(2):A401.
Greene (1977) A quantitative bioassay for nerve growth factor (NGF) activity employing a clonal pheochromocytoma cell line. Brain research. 133:350-353.
McDonald et al. (1991) New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor. Nature. 354:411-414.
Moore et al. (1975) The use of hybrid molecules in a study of the quilibrium between nerve growth factor monomers and dimers. Neurobiology. 5:369-381.
Petty et al. (1994) The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann. Neurol. 36:244-246.
Reed et al. (1987) Lysis of human red blood cells in the presence of various cosolvents. III. The relationship between hemolytic potential and structure. Journal of Parenteral Science & Technology. 41(1):37-39.
(1990) Remington's Pharmaceutical Sciences. 18thEdition, Mack Publishing Co., Easton, PA. pp. 1056, 1286, 1449.
Schmelzer et al. (1992) Biochemical characterization of recombinant human nerve growth factor. Journal of Neurochemistry. 59(5):1675-1683.
Thoenen et al. (1980) Physiology of nerve growth factor. Physiological Reviews. 60(4):1284-1335.
Timm et al. (1992) Equilibrium denaturation studies of mouse β-nerve growth factor. Protein Science. I:236-244.
Timm et al. (1994) Comparitive equilibrium denaturation studies of the neurotrophins: nerve growth factor, brain-derived neurotrophic factor, neurotrophin 3, and neurotrophin 4/5. Biochemistry. 33:4667-4676.
De Young Linda R.
Lam Xanthe M.
Nguyen Tue H.
Powell Michael F.
Agarwal Atulya R.
Allen Marianne P.
Dreger Ginger R.
Fox James A.
Genentech Inc.
LandOfFree
Stabilizing formulation for NGF does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilizing formulation for NGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilizing formulation for NGF will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516855